You are here

  • Home
  • Archive
  • Volume 89, Issue Suppl 1
  • P5.081 Analytical Evaluation of the GeneXpert ® CT/NG, the First Genetic Point of Care Assay For Simultaneous Detection of Neisseria Gonorrhoeae and Chlamydia Trachomatis

Article Text

Article menu

Download PDFPDF

P.05 - Translational and Implementation Sciences Track
P5.081 Analytical Evaluation of the GeneXpert ® CT/NG, the First Genetic Point of Care Assay For Simultaneous Detection of Neisseria Gonorrhoeae and Chlamydia Trachomatis
Free
  1. S N Tabrizi1,2,
  2. M Unemo3,
  3. D Golparian4,
  4. J Twin5,
  5. A E Limnios6,
  6. M Lahra6,
  7. R Guy7 on behalf of TTANGO Investigators
  1. 1Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Parkville, Australia
  2. 2Department of Obstetrics and Gynaecology, University of Melbourne, The Royal Women’s Hospital and Murdoch Childrens Research Institute, Parkville, Australia
  3. 3WHO Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden
  4. 43) WHO Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden
  5. 5The Royal Women’s Hospital, Parkville, Australia
  6. 64) WHO Collaborating Centre for STD, Microbiology Department, The Prince of UK Hospital, Randwick, Australia
  7. 7Kirby Institute, University of NSW, Sydney, Australia

Abstract

Introduction New assays for molecular detection of Neisseria gonorrhoeae and Chlamydia trachomatis need to be evaluated for potential false positive and false negative results due to cross reaction with other species, and potential mutations and genetic exchanges with other closely related organisms. Cepheid GeneXpert® CT/NG is the first FDA approved genetic point of care (POC) assay which simultaneously detects C. trachomatis, N. gonorrhoeae and controls for sample adequacy, in less than 90 minutes.

Method This study evaluated the GeneXpert® CT/NG assay with 372 characterised culture isolates; 111 N. gonorrhoeae isolates (including 3 isolates with N. meningitidis porA sequence), 223 isolates of non-gonococcal Neisseria species, 13 isolates of other species closely related to Neisseria and 25 C. trachomatis strains of different serovars (including LGV and nvCT strains).

Results All C. trachomatis and N. gonorrhoeae isolates were detected. A detection sensitivity of 10 genome copies per reaction was obtained with all C. trachomatis serovars as well as a representative N. gonorrhoeae control strain. Among the 223 non-gonococcal isolates, 4/11 N. mucosa and 2/42 N. subflava isolates were positive in one of the two N. gonorrhoeae targets (NG4), however the assay flagged all 6 as negative due to requirements of both NG targets being positive for the assay to display an N. gonorrhoeae positive result.

Conclusion GeneXpert® CT/NG assay was analytically highly sensitive and specific for detection of C. trachomatis and N. gonorrhoeae, showing great promise as a POC assay. Detection of two NG targets is highly advantageous for avoiding false positive N. gonorrhoeae results.

  • Molecular detection
  • point-of-care

https://doi.org/10.1136/sextrans-2013-051184.1125

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.